Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Endpoint Management and Adjudication Enhance Clinical Trials Platform

By BiotechDaily International staff writers
Posted on 17 Apr 2013
Endpoint adjudication management embedded within an electronic data capture platform optimizes the endpoint management and adjudication process, providing a collaborative and flexible workflow for all participants. Substantial cost effectiveness is achieved and cycle times reduced with a single, seamless system.

Merge Healthcare Incorporated (Chicago, IL, USA), a provider of clinical systems, recently added endpoint and adjudication management to its eClinical OS platform, providing end-to-end study support for trials of all sizes through a single platform.

“Merge eClinical has extensive experience working with the largest endpoint adjudication coordinating centers in the world. These relationships give us the unique experience to develop an endpoint adjudication module that is powerful, yet flexible enough to meet the complex requirements of all our clients. Merge’s latest enhancements to eClinical OS further our vision for delivering a unified solution for all data capture, processing, and return,” said Zaher El-Assi, general manager, eClinical solutions of Merge. “Through its single, easy-to-use interface, built-in study templates, libraries, and reports, and pay-as-you-go pricing, eClinical OS enables study sponsors and CROs to manage and run studies more efficiently than ever before.”

With Merge eClinical OS’ new Endpoint Adjudication Module, customers can: expedite cycle times with redaction tool and electronic compilation of source documents; auto-compile dossiers from source documents; reduce costs with fewer paper documents to track, ship, and review; Manage paired parallel, expert review and committee workflows; receive instant notifications that enable fast and efficient coordination; access reviewer assignments and dossiers from anywhere, at any time; and lastly, improve data quality through eCRFs and online edit checks.

“We began using eClinical OS towards the end of last year to manage and run our studies,” explained Thomas Engels, vice president of clinical affairs for CardioKinetix, Inc. (Menlo Park, CA, USA) “We’ve already seen enhanced efficiencies and improved productivity across the board, and are excited to begin using the new endpoint adjudication module to accelerate cycle times for adjudicating events.”

As a single, web-based system, Merge eClinical OS has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. With a complete menu of clinical trial capabilities that can be mixed and matched, eClinical OS builds a solid foundation for each trial environment. Merge eClinical OS also has the scalability to grow if a trial increases in size, number, or complexity.

“We are obviously pleased by the positive customer response to eClinical OS,” stated Zaher El-Assi, general manager, eClinical Solutions of Merge. “Customer feedback has been integral to the product design, and I think it reflects a renewed focus on study efficiency. Merge eClinical OS places the control back in the users’ hands, resulting in shorter build times, faster implementation, and more cost effective trial design.”

Related Links:
Merge Healthcare



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Illustration comparing a normal blood vessel and partially blocked vessel due to atherosclerotic plaque build-up (Photo courtesy of Wikimedia Commons).

Mutation Reducing Fatty Acid-Binding Protein Activity Lowers Heart Attack Risk

A team of Finnish cardiovascular disease researchers found that a mutation generating a low-expression variant of fatty acid-binding protein 4 (FABP4), reduced the risk of heart attack and stroke.... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.